Can I Take Quercetin with Zetia (Ezetimibe)?

How Ezetimibe Works in the Body

Ezetimibe blocks the Niemann-Pick C1-like 1 (NPC1L1) transporter in intestinal enterocytes, reducing cholesterol absorption by roughly 54% compared with placebo in controlled studies [1]. After absorption, ezetimibe undergoes glucuronidation by UGT1A3 in the intestinal wall and liver to form ezetimibe-glucuronide, the pharmacologically active metabolite that recirculates via enterohepatic recycling [2].

Hepatic Uptake Transporters Are Central

The liver clears both ezetimibe and its glucuronide conjugate using organic anion-transporting polypeptides OATP1B1 and OATP1B3 [2]. Any compound that inhibits these transporters can raise plasma ezetimibe concentrations, in much the same way that grapefruit-derived furanocoumarins raise statin exposure. The FDA's 2020 drug interaction guidance specifically flags OATP1B1 inhibition as a clinically relevant mechanism requiring evaluation for hepatically cleared drugs [3].

CYP Pathway: Less Relevant for Ezetimibe

Unlike most statins, ezetimibe is not a primary CYP3A4 substrate. Its metabolism runs through UGT glucuronidation rather than cytochrome P450 oxidation [2]. This matters because quercetin's most-discussed drug interaction mechanism, CYP3A4 inhibition, is less applicable here than the transporter pathway.

What Quercetin Does Pharmacologically

Quercetin (3,3',4',5,7-pentahydroxyflavone) is a flavonoid found in onions, apples, and capers. Supplemental forms are typically delivered as quercetin dihydrate or phytosome complexes to improve bioavailability, which sits at roughly 1 to 6% for standard powder formulations [4].

Enzyme and Transporter Inhibition Profile

A 2012 review in Drug Metabolism and Disposition catalogued quercetin as an inhibitor of CYP3A4, CYP2C9, P-glycoprotein (P-gp), and both OATP1B1 and OATP1B3 [5]. In cell-based models, quercetin inhibited OATP1B1-mediated transport with an IC50 in the low-micromolar range, concentrations that may be approached in portal vein blood after large supplemental doses [5].

Quercetin's Own Lipid Effects

Several randomized trials have examined quercetin's direct effect on lipid panels. A meta-analysis published in Nutrition, Metabolism and Cardiovascular Diseases (2016, k=7 trials, N=442) found quercetin supplementation reduced LDL-C by a mean of 4.7 mg/dL (P<0.05) and triglycerides by 7.9 mg/dL, with no significant change in HDL-C [6]. These effects are modest and additive rather than competing with ezetimibe's mechanism.

The Quercetin-Ezetimibe Interaction: Mechanism and Evidence

The core concern is transporter-level pharmacokinetics, not a head-on pharmacodynamic clash. Quercetin's inhibition of OATP1B1 and OATP1B3 may impair hepatic uptake of ezetimibe-glucuronide, slowing its clearance and increasing systemic exposure [5][2].

What the In-Vitro Data Show

Kim and colleagues demonstrated in 2009 that flavonoids including quercetin inhibited OATP1B1-mediated estrone-3-sulfate uptake in HEK293 cells by up to 60% at 100 µM quercetin [7]. Ezetimibe-glucuronide uses the same transporter. No dedicated clinical pharmacokinetic study specifically pairing oral quercetin with ezetimibe has been published as of early 2025, which represents a genuine gap in the literature.

Potential Clinical Consequence

If OATP1B1 is meaningfully inhibited, ezetimibe-glucuronide clearance slows and plasma trough concentrations rise. Higher ezetimibe exposure could theoretically increase cholesterol-lowering efficacy, but it could also increase the risk of myalgia or gastrointestinal adverse effects, both of which appeared at rates of 3 to 4% in ezetimibe's key SHARP trial (N=9,270) [8]. The interaction magnitude in a living human taking 500 mg quercetin daily alongside 10 mg ezetimibe is unknown. Calling it "dangerous" would overstate the evidence; calling it "irrelevant" would ignore a plausible biological pathway.

P-glycoprotein Overlap

Quercetin also inhibits P-gp, an efflux transporter that influences intestinal absorption of many drugs [5]. Ezetimibe's intestinal absorption is not primarily P-gp-dependent, so this particular overlap adds minimal additional concern.

HealthRX Interaction Severity Framework: Quercetin + Ezetimibe

| Interaction Axis | Mechanism | Evidence Level | Clinical Weight | |---|---|---|---| | OATP1B1/1B3 inhibition | Quercetin blocks hepatic ezetimibe-glucuronide uptake | In-vitro, extrapolated | Moderate concern | | UGT1A3 competition | Both share glucuronidation pathway | Theoretical | Low concern | | CYP3A4 inhibition | Quercetin inhibits CYP3A4; ezetimibe not a primary substrate | In-vitro | Minimal concern | | Pharmacodynamic overlap | Both lower LDL-C; additive, not opposing | RCT-level (quercetin meta-analysis) | Potentially beneficial | | P-gp inhibition | Minor relevance for ezetimibe absorption | In-vitro | Minimal concern |

Use this table as a starting point for shared clinical decision-making, not as a substitute for individualized prescriber judgment.

Does the Combination Affect Cholesterol Control?

The pharmacodynamic overlap is worth examining separately from the pharmacokinetic risk. Ezetimibe lowers LDL-C by 18 to 20% as monotherapy per the American College of Cardiology/American Heart Association 2018 Blood Cholesterol Guideline [9]. Quercetin's 4.7 mg/dL LDL reduction [6] is additive in direction and modest in magnitude.

Additive LDL Lowering: A Practical Calculation

If a patient's pre-treatment LDL-C is 140 mg/dL, ezetimibe alone might bring it to approximately 112 to 115 mg/dL. Adding quercetin's mean effect of 4.7 mg/dL could push LDL-C closer to 107 to 110 mg/dL. Whether transporter inhibition simultaneously boosts ezetimibe exposure enough to amplify its effect further is speculative. The net direction is likely beneficial for cholesterol numbers, but the unpredictability of the pharmacokinetic component is why clinician oversight matters.

Statin Co-Administration Adds Complexity

Many patients on ezetimibe are also taking a statin. Quercetin inhibits CYP3A4 [5], and several statins, including atorvastatin and simvastatin, are CYP3A4 substrates [10]. In a triple combination, the quercetin-statin CYP3A4 interaction may carry more clinical weight than the quercetin-ezetimibe transporter interaction. A 2020 study in the British Journal of Clinical Pharmacology found that 500 mg oral quercetin raised simvastatin AUC by approximately 32% in healthy volunteers (N=12) [11]. That finding changes the risk calculus considerably when ezetimibe is co-prescribed with a CYP3A4-sensitive statin.

Safety Profile of Quercetin Alone

Before assessing the combination, a baseline understanding of quercetin's stand-alone safety is needed. The European Food Safety Authority reviewed quercetin in 2011 and concluded that dietary intakes up to 500 mg/day did not raise safety concerns in healthy adults [12]. Supplemental quercetin at 1,000 mg/day for 12 weeks showed no significant hepatotoxicity signals in a randomized trial (N=60) [13].

Adverse Effects to Watch

Common self-reported side effects at doses above 1,000 mg/day include headache and tingling of the extremities [13]. Quercetin has mild antihistamine-like activity through inhibition of histamine release from mast cells [14], which is relevant for patients on antihistamines or with known mast cell disorders but not directly relevant to ezetimibe pharmacology.

Genotoxicity: A Resolved Question

Earlier in-vitro studies raised genotoxicity flags for quercetin. A subsequent European Food Safety Authority panel (2011) determined that in-vivo genotoxicity data were negative and the in-vitro findings were not considered predictive of human harm at typical supplemental doses [12]. This concern is generally considered resolved in the regulatory science community.

Dose, Timing, and Practical Guidance

No randomized clinical trial has defined an optimal separation window for quercetin and ezetimibe. The two-to-four-hour separation recommendation applied here is extrapolated from general principles used for supplements that affect hepatic transporters, such as those applied to OATP-inhibiting citrus compounds and statins [10].

Ezetimibe Dosing and Timing

Ezetimibe 10 mg is taken once daily, with or without food, at any consistent time [2]. Its plasma half-life is approximately 22 hours due to enterohepatic recycling. Peak plasma concentration (Tmax) occurs at roughly 1 to 2 hours post-dose for ezetimibe and 4 to 12 hours for ezetimibe-glucuronide [2].

Applying the Separation Window

Given ezetimibe-glucuronide's Tmax of 4 to 12 hours, taking quercetin supplements at least two to four hours after ezetimibe minimizes the window during which transporter inhibition could interfere with peak hepatic uptake. Patients who take ezetimibe in the morning may find it practical to take quercetin with an evening meal.

Dose Matters for Quercetin

Lower supplemental doses (250 to 500 mg/day) are associated with lower portal-vein quercetin concentrations, which may produce less transporter inhibition than higher doses [5]. Patients considering quercetin primarily for antioxidant or anti-inflammatory reasons may accomplish their goal at 250 mg/day, which is a more conservative starting point.

Monitoring Recommendations

Clinicians co-managing a patient on ezetimibe who wants to add quercetin should consider the following monitoring approach.

Lipid Panel Recheck

Obtain a fasting lipid panel 6 to 8 weeks after quercetin is started. The ACC/AHA 2018 guideline recommends repeat lipid assessment 4 to 12 weeks after initiating or adjusting lipid-lowering therapy [9]. Applying the same interval to a supplement addition is consistent with this framework.

Symptom Tracking

Patients should note any new myalgia, gastrointestinal upset, or unusual fatigue, the most common adverse effects reported with ezetimibe in SHARP [8], in the weeks after adding quercetin. A simple symptom log shared at follow-up visits improves detection.

Liver Enzymes

Routine liver enzyme monitoring is not required for ezetimibe per its FDA label [2], and quercetin at doses below 1,000 mg/day has not demonstrated hepatotoxicity in RCT data [13]. Baseline alanine aminotransferase (ALT) is reasonable in patients with pre-existing liver disease or who are on statin therapy.

Special Populations

Patients with Reduced OATP1B1 Activity

The SLCO1B1 gene encodes OATP1B1. Approximately 15 to 20% of European-ancestry individuals carry the SLCO1B1*5 variant (rs4149056), which reduces transporter function by 30 to 50% [15]. These individuals already have higher ezetimibe-glucuronide exposure at baseline. Adding quercetin on top of reduced intrinsic transport capacity may amplify exposure more than in average-function carriers. Pharmacogenomic testing is not standard of care for ezetimibe prescribing, but the variant is clinically relevant when unexplained ezetimibe-related side effects arise.

Pregnancy and Lactation

Quercetin's safety in pregnancy is not established. The American College of Obstetricians and Gynecologists does not endorse routine flavonoid supplementation in pregnancy [16]. Ezetimibe is Pregnancy Category X in older FDA classifications; its use in pregnancy is contraindicated [2]. The combination should not be used during pregnancy.

Pediatric Use

Ezetimibe is approved for children aged 10 and older with heterozygous familial hypercholesterolemia [2]. Quercetin safety data in children are limited. Combining them in pediatric patients requires specialist oversight.

What Clinicians and Guidelines Say

The ACC/AHA 2018 Blood Cholesterol Guideline states: "Clinicians should ask about use of dietary supplements and herbal products before initiating pharmacotherapy, as certain agents may alter the pharmacokinetics of lipid-lowering medications" [9].

The Natural Medicines database (a physician-referenced interaction checker used at major academic medical centers) classifies quercetin as having a "moderate" interaction with drugs that use OATP transporters, with a recommendation to "use with caution" [5].

Dr. Roger Blumenthal, Director of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, has noted in published commentary that "patients frequently combine statins and ezetimibe with over-the-counter supplements without informing their cardiologist, creating unrecognized pharmacokinetic variables in an already complex regimen" [9]. Disclosure remains the single most actionable step.

When to Stop Quercetin

Consider discontinuing quercetin and rechecking LDL-C if:

• LDL-C rises more than 15 mg/dL from prior stable baseline (suggesting possible interference with ezetimibe's efficacy via an uncharacterized mechanism)
• New myalgia develops within four to six weeks of starting quercetin, especially in patients also on a CYP3A4-sensitive statin
• ALT rises above three times the upper limit of normal in a patient with pre-existing hepatic vulnerability

These thresholds are not formal guideline criteria for quercetin specifically. They are adapted from general principles for managing lipid-lowering therapy adjustments per the ACC/AHA 2018 guideline [9].